Financial Results (Q4 FY2022) - QoQ Comparison

The company has reported a total income of Rs. 5324.35 crore during the period ended March 31, 2022 as compared to Rs. 5570.15 crore during the period ended December 31, 2021.

The company has posted a net profit of Rs. 362.07 crore for the period ended March 31, 2022 as against a net profit of Rs. 728.60 crore for the period ended December 31, 2021.

Financial Results (Q4 FY2022) - YoY Comparison

The company has reported a total income of Rs. 5324.35 crore during the period ended March 31, 2022 as compared to Rs.4666.58 crore during the period ended March 31, 2021.

The company has posted a net profit of Rs.362.07 crore for the period ended March 31, 2022 as against net profit of Rs.413.38 crore for the period ended March 31, 2021.

Financial Results (Year Ended FY2022) - YoY Comparison

The company has reported a total income of Rs.22044.25 crore during the Financial Year ended March 31, 2022, as compared to Rs.19425.58 crore during the Financial Year ended March 31, 2021.

The company has posted a net profit of Rs.2516.75 crore for the Financial Year ended March 31, 2022, as against net profit of Rs.2404.87 crore for the Financial Year ended March 31, 2021.

“I am pleased to see the continued momentum across our key markets despite adverse seasonality impacting the overall business mix. Our One-India business continued the double-digit trajectory during the quarter. We crossed the US $ 1Bn milestone in our domestic branded prescription business driven by the sustained growth across our acute and chronic portfolio. Our established respiratory franchise and contribution from peptide assets have strengthened our US run rate to US $ 160Mn. Adjusting for covid linked and other one-time charges, our core operating profitability continues to be strong underpinned by the strength of our business fundamentals. We continue to respond to challenging input cost environment with cost optimization and mix management while maintaining high serviceability. We are excited about the upcoming complex launches in H2FY23 which will further strengthen overall business and profitability trajectory.”  Umang Vohra MD and Global CEO, Cipla